Non-small cell lung cancer-associated nucleic acid variants (NSCLC variants)

NSCLC-associated nucleic acid variants represent a broad category of genomic alterations, including point mutations, small insertions/deletions, and chromosomal rearrangements, that serve as primary drivers in the pathogenesis of non-small cell lung cancer (NSCLC). These variants occur in critical genes such as EGFR, KRAS, ALK, ROS1, BRAF, MET, RET, and HER2, leading to the constitutive activation of intracellular signaling cascades that promote cell proliferation, survival, and metastasis (Source: Nature Reviews Cancer, 2020). In the era of precision oncology, these nucleic acid variants are utilized as essential predictive biomarkers to match patients with specific targeted therapies, such as tyrosine kinase inhibitors (TKIs) (Source: NCCN Guidelines, 2023). While the variants are the genetic markers identified through diagnostic assays like next-generation sequencing (NGS), the therapeutic drugs are designed to inhibit the aberrant proteins produced by these altered sequences (Source: Journal of Clinical Oncology, 2021). The clinical management of NSCLC is heavily dependent on the identification of these variants, as they dictate the standard of care for advanced-stage disease (Source: Lancet Oncology, 2022). Despite the success of targeted agents, the dynamic nature of the cancer genome often leads to the development of secondary resistance mutations, necessitating ongoing genomic monitoring (Source: Cancer Discovery, 2022).

Other names

NSCLC genomic alterationsNSCLC driver mutationsLung cancer biomarkersNSCLC somatic mutationsNSCLC molecular markers

Targeted inhibition of mutant proteins encoded by specific nucleic acid variants, primarily through tyrosine kinase inhibition or covalent binding to specific mutant residues.